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Abstract: Urinary incontinence (UI) is a common health problem affecting quality of life of nearly
420 million people, both women and men. Pelvic floor muscle (PFM) training and other physiotherapy
techniques play an important role in non-surgical UI treatment, but their therapeutic effectiveness is
limited to slight or moderate severity of UI. Higher UI severity requires surgical procedures with pre-
and post-operative physiotherapy. Given that nearly 30%–40% of women without dysfunction and
about 70% with pelvic floor dysfunction are unable to perform a correct PFM contraction, therefore, it
is particularly important to implement physiotherapeutic techniques aimed at early activation of
PFM. Presently, UI physiotherapy focuses primarily on PFM therapy and its proper cooperation with
synergistic muscles, the respiratory diaphragm, and correction of improper everyday habits for better
pelvic organ support and continence. The purpose of this work is a systematic review showing the
possibilities of using physiotherapeutic techniques in the treatment of UI in women with attention to
the techniques of PFM activation. Evidence of the effectiveness of well-known (e.g., PFM training,
biofeedback, and electrostimulation) and less-known (e.g., magnetostimulation, vibration training)
techniques will be presented here regarding the treatment of symptoms of urinary incontinence
in women.
Keywords: incontinence; physiotherapy; biofeedback; electrostimulation; vibration; magnetic
stimulation; pelvic floor muscle training
1. Introduction
Urinary incontinence (UI), characterized by involuntary loss of urine (ICS—International
Continence Society), is a serious social and health issue whose incidence is increasing [1]. UI is
diagnosed more often in women than in men [2], and in 2018, it was predicted to affect nearly
420 million people (300 million women and 120 million men) worldwide [1]. However, this number
may be underestimated because of the intimate nature of UI.
The main types of UI are stress UI (SUI), urge UI (UUI), and mixed UI (MUI) [3]. Briefly, SUI
is characterized by loss of urine as a consequence of an increase in intra-abdominal pressure, which
results in an increase in intravesical pressure that exceeds the maximum urethral closure pressure.
This situation occurs, for example, during coughing, sneezing, or jumping [4]. In UUI, loss of urine
occurs with sudden, strong urgency that is inadequate to the degree of bladder filling [5]. MUI
combines the symptoms of the above two types, and the involuntary loss of urine is associated with
urgency and/or increase in intra-abdominal pressure [6].
The etiology of UI is multifactorial, and its causes are mainly associated with the dysfunction of
the bladder, pelvic floor muscles (PFMs) [7], the ligament apparatus [8], connective tissue including,
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inter alia, endopelvic fascia and/or neural structures [9]. The risk of UI increases with age [10,11], but it
can also occur after delivery as well as in young nulliparous women [12]. The main risk factors of UI
development include the following: predisposing factors, such as genetic factors and gender, factors
associated with damage of the continence mechanism (e.g., abdominal surgery, multiple births), and
promotional factors, such as overweight/obesity, menopause, drugs, and urinary tract infections [13]. UI
treatment includes surgical and conservative methods, among which physiotherapy is recommended
as the first line of therapy because of its effectiveness, low cost, and low risk associated with it.
2. Incontinence—Impact on Quality of Life and Economic Status
Studies show that UI significantly reduces women’s quality of life [14–17]. Shame, anxiety, and
fear of unpleasant smell or uncontrolled loss of urine lead to withdrawal of the affected women from
social life. Women suffering from UI are characterized by a higher degree of emotional disorders than
those with normal micturition [18,19]. According to Felde et al. [20], women with UI are more likely
to suffer from depressive disorders and anxiety. UI also has a negative effect on the women’s sex
life [21,22] and reduces self-esteem [23]. Women with UI avoid sexual intercourse due to the possibility
of urine leakage. Nearly 50%–68% of women with incontinence have been shown to suffer from sexual
dysfunction [22]. With the development of UI, the risk of falls and injuries due to frequent necessity to
use the toilet increases [24]. Older women diagnosed with UI are 1.5 to 2.3 times more likely to fall,
which results in a worsening of overall health and increased healthcare costs [25]. In addition, because
of fear of lack of control over voiding, the level of physical activity is also reduced [14]. Attention
should also be paid to reduction in the economic level of patients and high treatment costs [16]. UI has
a negative effect on women’s working lives (absenteeism, lower efficiency, and lower work pace) [17];
moreover, expenses for the purchase of underwear, absorbent pads, and diapers are increasing [26].
The average annual cost of treatment of women with UI in Germany was € 515, in Spain € 655, and in
Great Britain/Ireland € 395, where absorbent pads accounted for nearly 51% of the treatment cost [27].
Koening et al. estimated that the total annual cost of treatment for one woman with UI is nearly 22%
higher than the average cost of treatment for the general female population in 2017 in Switzerland [28].
3. Role of Pelvic Floor Muscle in Continence
The pelvic floor (PF) consists of passive (ligaments, fascia) and active (muscles) components that
support the bladder, reproductive organs, and rectum [29]. The proper cooperation between the soft
tissue components and the appropriate action determine the proper closing and opening of the key
areas such as the urethra (micturition), vagina (delivery), or rectum (defecation). Therefore, in addition
to maintaining organ statics, they also affect the proper course of labor, voids, or defecation as well as
fecal and urine continence [30,31].
Studies have shown that pelvic floor muscles (PFMs) together with internal oblique, intercostal
muscles, transverse abdominal muscle, and diaphragm are responsible for maintaining proper body
posture and breathing [32,33]. Due to numerous myofascial connections between PFM and other
muscles all movements are functionally linked, and throughout this system, PFM exists as the basis for
local stabilization [33,34]. For this reason, myofascial disorders as well as posture disorders can lead to
impaired PFM function and, consequently, their weakness and UI [35].
In physiotherapeutic examination PFM function is evaluated using the PERFECT scale assessing
strength of voluntary contraction (P), endurance (E), slow-twitch muscle fiber performance (R),
fast-twitch muscle fiber performance (F), PFM contraction pattern (E), co-contraction of the transverse
abdominal muscle (C) and involuntary contraction in response to increased intra-abdominal pressure
(T) [36,37]. PFM strength is assessed using a 6-stage Modified Oxford Scale [36,38]. The most common
diagnoses are overactive or underactive PFM. An overactive PF is not able to relax after any contraction
or in a situation where relaxation is required, e.g., voiding or defecation, while underactive PFM is
unable to perform voluntary or involuntary contraction necessary for, e.g., pelvic organ stabilization
against lowering during increasing of intra-abdominal pressure [3,39].
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The improper PFM tonus leads to many disfunction [29,40]. Research indicates that increased
tone of PFMs can prolong delivery course, while simultaneously favoring greater damage within
them [41,42]. PF hypertonicity frequently occurs in women with chronic pelvic pain [40], but may also
leads to incontinence caused by increased intra-abdominal pressure. It is known that the persistent state
of excessive muscle tension leads to a weakening of their strength and endurance. Excessive tension
of the pubic-rectal muscle, by reducing the anorectal angle, may also result in hindered defecation
and increases the need for displacement using a stronger abdominal compressor [43]. Similarly, in the
case of voiding, excessive PFM tension may functionally hinder its initiation, resulting in the necessity
of using the abdominal pressure [44]. This condition also favors the occurrence of constipation and,
consequently, may increase the risk of hemorrhoids [44]. Abuse of the abdominal press is also one
of the factors increasing the risk of lowering within the pelvic organs [45]. Therefore, control and
normalization of PFM tone can be an important factor for maintaining the functional balance of the
complex [46].
4. Materials and Methods
The aim of this paper is a systematic review showing the possibilities of using physiotherapeutic
techniques in the treatment of UI in women with attention to the techniques of PFM activation.
The review of the literature was carried out in the Medline-PubMed database. Keywords varied
depending on the therapy: PF training AND urinary incontinence; electrotherapy AND urinary
incontinence; urinary incontinence AND magnetic stimulation OR Extracorporeal Magnetic Innervation;
whole-body vibration OR vibrance OR vibration OR perineal stimulation OR intravaginal vibratory
AND urinary incontinence.
Inclusion and exclusion criteria. The review included works that were published in the years
2009–2020 in English. The research should have been carried out on women with diagnosis of UI.
Publications should investigate the impact of various physiotherapeutic methods on the treatment of
UI. Exclusion criteria included studies not related to women with UI, publications in English made or
published before 2009, non-RCTs studies and study protocols. Other exclusion criteria were pregnancy
or puerperium period < 6 weeks, cancer, neurological and spine diseases, no access to the full-text
version of articles.
5. Results
A total of 1602 references were found. Based on the analysis of titles and abstracts, 1538 publications
were rejected. A total of 64 articles were left to read in full. Finally, 32 papers were qualified for
the review (Figure 1): 11 publications on PFM training, 8 on electrical stimulation, 6 on magnetic
stimulation, and 7 on whole-body vibration training were qualified for review.
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6. Physiotherapeutic Techniques in UI
6.1. Pelvic Floor Muscle Training
Pelvic floor muscle training (PFMT) is a well-described, effective, and most commonly used
method of physiotherapeutic UI treatment which has been recognized and recommended as the first
line of conservative SUI treatment [47]. For the first time, PFM exercises were described in 1948
by Arnold Kegel as a behavioral method in the treatment of UI [48]. Their effectiveness is proven
regardless of age and BMI [49]. PFMT is based on two pelvic muscle functions: pelvic support and
cooperation in the urethral sphincter closing mechanism [50]. A PFMT can be performed to increase
strength, endurance, and muscle coordination [51]. The studies estimate that regular PFMT deceased
loss of urine and improved quality of life [52]. However, research shows that nearly 30%–40% of
women are unable to perform the correct voluntary PFM contraction despite the instruction [53] and
in the population of women with pelvic floor dysfunction, this value increases to 70% [54]. In this
situation, it is necessary to use facilitating techniques for the teaching of PFM voluntary contraction,
because PFMT alone will not yield the assumed outcomes [46].
De Andrade et al. confirmed that giving only the instruction of PFM exercise increased knowledge
about the PF but was not effective in contracting and strengthening the PFM [55]. However, there
are also studies that confirm the effectiveness of PFMT performed at home with app-based audio
guidance after prior instruction. Exercises with voice guidance are more effective than conventional
exercises [56].
Unfortunately, most randomized studies on the effectiveness of PFMT include patients
who can perform voluntary PFM contraction in their inclusion criteria [57,58]. According to
Mateus-Vasconcelos et al. [59], effective facilitating techniques include vaginal palpation with or
without posterior pelvic tilt and electrostimulation, however, with much lower efficiency. These
techniques should be used when the strength of PFM contraction is 0–1 on the Modified Oxford Scale
(MOS) [59]; patients with higher MOS value (2 and more) respond well to PFMT therapy [57,58].
It should also be noted here that PFMT can be conducted both in a form supervised by a physiotherapist
as well as in an unattended form at the patient’s home. Studies have shown that unattended training
is significantly less effective at relieving UI symptoms than supervised training [60]. However, the
effectiveness of home unsupervised training can be increased using additional techniques such as
electrostimulation [61], biofeedback (BF) [62], or vaginal cones [63]. A detailed description of the
studies included in the review is presented in Table 1.
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Table 1. Characterization of selected studies on the effects of pelvic floor muscle training on the pelvic floor muscles (PFM) activity and/or severity of urinary
incontinence symptoms.
Reference Main Objective Patients Characteristic Study Description Outcome
Alves et al. (2015) [58]
Verification of the effect of






66.11 ± 8.72 years)
Control: 12 (aged
65.67 ± 9.21 years)
Control: 12 fitness session for 60 min,
twice a week, per 6 weeks, instruction
about the PFM function and the correct
way to contract it, without PFMT.
Intervention: Individually teaching the
exercises to follow with the Gym Ball,
pelvic mobility, stretching, strengthening
and relaxation exercises in five positions
(supine, sitting on the floor, on the Gym
Ball, squat and standing), with the PFM
contractions (8 s hold—16 s relax). 12
sessions of 30 min, twice a week, six
weeks treatment.
Assessment: sEMG, MOS, ICIQ UI-SF,
ICIQ-OAB, ICIQ-VS
PFMT increased PFM contractility and
decreased anterior pelvic organ
prolapse and urinary symptoms.
McLean et al. (2013) [64]
Verification of the effect of
PFMT on urethral morphology
and mobility in women
with SUI.
35 women with SUI
Control: 17 (aged
54.0 ± 8.4 years)
Intervention: 18 (aged
49.5 ± 8.2 years)
Control: no intervention
Intervention: supervised PFMT 30 min
per day, for 12 weeks
Assessment: MOS, 3-day bladder diary,
pad test, UDI-6, IIQ-7,
ultrasound evaluation
The intervention group showed a
reduced bladder neck mobility during
coughing and increased cross-sectional
area of their urethra (from baseline to
the end of the study). Similar results
were not obtained in the control group.
Intervention group showed statistically
significant changes in urine leakage
(3-day bladder diary) and in results of
IIQ-7. Similar significance was not
obtained for pad test and UDI-6. The
control group did not achieve
significant improvement in
any parameters.
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Table 1. Cont.
Reference Main Objective Patients Characteristic Study Description Outcome
Celiker Tosun et al.
(2015) [65]
Checking whether pelvic floor
muscle training and increasing
PFM strength will eliminate
UI symptoms.
121 women
Intervention group (IG): 58
(aged 51.7 ± 10.3)
Control group (CG): 63
(aged 52.5 ± 9.1)
Intervention group: For the first two
weeks, patients had 3 sessions (30 min)
with a physiotherapist. They received a
posture training. Then individual PFM
exercise schedules were designed for
patients (home-based exercise program).
This part of study lasts 12 weeks. If
someone did not increase muscle
strength to 5 on the Oxford Scale, they
could continue participating in the study.
Control group: no treatment
Assessment: IIQ-7, UDI-6, bladder diary,
stop test, pad test, the PERFECT scale,
the perineometer, and ultrasound, the
Oxford Scale
The IG group demonstrated a
significant improvement in all
examined aspects after study. Similar
results were not obtained in CG group.
In the intergroup analysis comparing
the results after 12 weeks of the study,
the training group achieved a
significant improvement in the
parameters tested compared to the
control group. All people who
continued to exercise to achieve PFM
strength on 5 on the Oxford Scale
obtained a significant improvement in
UI symptoms.
Nascimento-Correia
et al. (2012) [66]
Assessment of effects of
kinesiotherapy on function and
level of pressure of PFM and
quality of life of women with UI.
30 women
Intervention group (IG): 15
(age 60.20 ± 8.16)
Control group (CG): 15 (age
61.53 ± 10.12)
Intervention group: 12 sessions of
one-hour PFMT, once a week
Control group: no treatment
Assessment: the 1 h pad test, KHQ, the
PERFECT scale, the perineometer
The IG group showed a significant
improvement in urinary leakage (pad
test), function of PFM (the PERFECT
scale) and PFM pressure (the
perineometer) and in some aspects of
KHQ. Similar results were not obtained
in CG group. In the intergroup analysis
in all the above aspects statistically
significant differences were obtained in
favor of the IG group than CG.
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Table 1. Cont.
Reference Main Objective Patients Characteristic Study Description Outcome
Pereira et al. (2011) [67]
Assessment of effectiveness of
PFMT in group treatment
sessions (GT), individual
sessions (IT) and control group
(CG) in women with SUI.
45 women
GT group: 15 women (age
60.2 ± 8.16)
IT group: 15 women (age
60.6 ± 12.63)
Control group: 15 women
(age 61.53 ± 10.11)
Intervention: GT group—PFMT group
treatment session, IT group—PFMT
individual treatment session, Control
group—no treatment. Exercises in the
training groups were performed for 6
weeks, 2 sessions a week for 1 h.
Assessment: KHQ, a perineometer, the
PERFECT scale, MOS, the 1 h pad test
IT group obtained a significant
decrease in urinary loss (pad test). A
similar effect was obtained in the
intergroup analysis (GT vs. CG, IT vs.
CG). GT and IT group presented a
significant increase of the pressure
perineometry of PFM. After the
treatment, significant differences in this
aspect were demonstrated between the
groups GT vs. CG and IT vs. CG.
Muscle strength increased significantly
after therapy only in group GT and IT
(the 6-point Modified Oxford Scale).
Kashanian et al. (2011)
[68]
Assessment of the effectiveness
of PFM training without or
using a resistance device in
women with UI.
85 women with UIAPFMT
(assisted PFMT) group: 39
women (age 39.07 ± 6.18)
PFMT group: 46 women
(age 40.56 ± 6.18)
PFMT group: Kegel
exercises—contraction: relaxation 6–8 s: 6
s. Time: 15 min, 2 times a day for 12
weeks. APFMT group: after PFMT, the
Kegelmaster was used twice a day for 15
min of each session for a total of 12 weeks.
Assessment: MOS, I-QOL, IIQ, UDI, VAS
In both groups there was an
improvement in UI severity, number of
UI episodes, PFM strength and
participation in social life (these were
not significantly different in
intergroup analysis).
Compared to the PFMT group, side
effects occurred in the APFMT group
(vaginal discharge, pain, spotting).
UI—urinary incontinence, PFMT—Pelvic Floor Muscle Training, sEMG—surface electromyography, MOS-Modified Oxford Scale, ICIQ UI-SF—International Consultation on Incontinence
Questionnaire—Short Form, ICIQ-OAB—International Consultation on Incontinence Questionnaire Overactive Bladder, ICIQ-VS—International Consultation on Incontinence Questionnaire
on Vaginal Symptoms, IIQ-7—Incontinence Impact Questionnaire-7, UDI-6—Urogenital Distress Inventory-6, I-QOL—Incontinence Quality of Life, VAS—Visual Analog Scale.
J. Clin. Med. 2020, 9, 1211 9 of 32
Studies show that the effectiveness of PFMT increases significantly if the BF technique is used.
It should be emphasized that BF is not a method of therapy but a form of its support, allowing for a better
feeling and imaging of the structures and muscles that we want to activate and strengthen. Currently,
in PFMT, it is possible to use many forms of BF; the most common is the surface electromyography
(sEMG) method using a vaginal probe that allows the physiotherapist to read the electrical activity of
the PFMs [69] and use this information to design exercise tasks, programs, or games for the patient
depending on her level of advancement. Because of the use of BF, patients can correctly identify
contracting muscles and perform their activity depending on the training task, which is usually
illustrated by animation or playing a game on the screen. Other forms of BF currently used in
urogynecological physiotherapy is pressure BF using a vaginal probe that reads pressure changes
caused by PFM contraction—the principle of its operation is analogical to the perineometer [70].
PFM contraction can also be visualized using BF combined with ultrasound, which is so-called
“sonofeedback” [71]. The effect of exercise with biofeedback on UI has been the subject of numerous
studies [63,72], which showed that BF can be an effective support for the training process.
The other type of training PFM can be hypopressive exercises (HE) proposed by Caufriez.
HE relies on the reflex activation of PFM through adequate breathing and body position changes.
They also activate the transverse abdominal muscle, increase PFM endurance, but do not lead to
their hypertrophy [73]. An important factor affecting the effectiveness of PFM training is the proper
positioning of the pelvis and ankle. Studies show that a greater contraction of PFM and postural
muscles occurs during ankle dorsiflexion [74]. These studies provide a valuable tip for conducting the
most effective PFM exercises. A detailed description of the studies included in the review is presented
in Table 2.
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Table 2. Characteristic of selected studies on the effects of pelvic floor muscle training and biofeedback on the pelvic floor muscles (PFM) activity and/or severity of
urinary incontinence symptoms.
Reference Main Objective Patients Characteristic Study Description Outcome
Bertotto et al. (2017) [75]
Evaluation of the effectiveness








Control group: 14 (age
57.1 ± 5.3)
PFMT group: 15 (age
59.3 ± 4.9)
PFMT + BF group: 16
(age 58.4 ± 6.8)
Intervention: PFMT group—PFM
exercises—8 sessions, twice a week for 20
min for 4 weeks, PFMT + BF group—8
sessions of PFM exercises with BF, twice a




The PFMT and PFMT+BF group present a
significant improvement in muscle strength
as compared to control group (the Modified
Oxford Scale). Based on EMG, better PFM
function was achieved in groups PFMT and
PFMT+BF. The PFMT+BF group also
achieved significant improvements
compared to the PFMT group (the
Modified Oxford Scale, EMG). Significant
improvement was also obtained in QOl
(only in PFMT and PFMT+BF groups).
Fitz et al. (2017) [76]
Assessing whether biofeedback
added to pelvic floor muscle
training increases exercise
frequency in women with SUI.
72 women with SUI
PFMT group: 37 (age
56.6 ± 12.0)
PFMT + BF group: 35
(age 56.1 ± 10.5)
Intervention: Both groups performed
outpatient and home PFM exercises for 3
months, BF group also get a vaginal BF
equipment. The outpatient trainings were
supervised by a physiotherapist (24 session
for 3 months, twice a week for 40 min).
Home PFM exercises consisted of three sets
of 10 repetitions daily for 3 months. From
4th to 9th months women from both groups
performed PFM exercises only at home.
Assessment: A voiding diary, a modified
20-min pad test, an exercise diary, the
Oxford Grading Scale, a Peritron
manometer, I-QOl.
Both groups present a significant reduction
in the number of episodes of urine loss (a
voiding diary), in the urine leakage (a pad
test) (from baseline to 3 and 9 months).
Both groups significantly improved a PFM
function (PFMT group did not obtain a
significant difference for the measurement
from baseline to 9 months). Both groups
showed significantly better quality of life
(I-QOl). There were no significant
differences between groups.
There were no differences between groups
in the number of monthly training, weekly
frequency (days/week) and exercises sets
per day after 3 months of supervised
treatment and at 9-month follow-up.
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Table 2. Cont.
Reference Main Objective Patients Characteristic Study Description Outcome
Hirakawa et al. (2013)
[77]
Comparison of the effectiveness
of pelvic floor muscles training
(PFMT) with or without
biofeedback (BF) in women
with SUI.
46 women
PFMT group: 23 (age
58.3 ± 11.2)
PFMT + BF: 23 (age
55.3 ± 9.8)
Intervention: PFM training (for 12 weeks)
twice a day: 10 maximum contractions for
5 s + 10 s of relaxation. Then 10 quick
maximum contractions with a 2 s hold + 4 s
relaxation—performed twice with 1 min
break between sets. Women from BF group
also get EMG-assisted home
training device.
Assessment: KHQ, ICIQ-SF, a voiding
diary, 1 h pad test, perineometer for
PFM strength.
In both groups, there was a significant
improvement in the women’s quality of life
(KHQ) and subjective symptoms (ICIQ-SF).
Reduction of UI episodes (voiding diary)
were significant only in PFMT group, in BF
group showed a tendency to decrease
episodes of UI, but it was not statistically
significant. Both groups showed a
tendency to decrease the leakage volume
(1 h pad test). In both groups a maximum
vaginal pressure (perineometer)
increased significantly.
There were no significant differences
between groups.
Huebner et al. (2011)
[57]
Comparison of three different
strategies: (1) EMG
biofeedback-assisted PFMT and
conventional ES; (2) EMG
biofeedback-assisted PFMT and





Group 1: EMG biofeedback-assisted PFMT
and conventional ES (50 Hz, 20–80 mA,
stimulation 8 s, rest 8 s, active contraction 8
s, rest 15 s), 15 min twice a day per
3 months
Group 2: EMG biofeedback-assisted PFMT
and dynamic ES (50 Hz, 20–80 mA, active
contraction 8 s, after gaining the max
contraction, ES was added, Stimulation 8 s,
rest 15 s), 15 min twice a day per 3 months
Group 3: EMG biofeedback-assisted PFMT
(active contraction 8 s, rest 15 s), 15 min
twice a day per 3 months
Assessment: KHQ, number of pads, pad
weight test, digital vaginal palpation, MOS,
intravaginal EMG.
In all groups QOL (KHQ) significantly
improved over the 12-week. In all three
groups, the contractility of PFM (MOS,
EMG) significantly increased. The number
of pads used per day decreased and the
pad weight test showed a significant
improvement for every group. There are
no differences between groups. The
additional ES did not show any benefits.
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Table 2. Cont.
Reference Main Objective Patients Characteristic Study Description Outcome
Chmielewska et al.
(2019) [78]
Comparison of the effectiveness
of pelvic floor muscles training
with surface electromyographic
(sEMG) biofeedback (BF) with
Pilates exercises (PG) in women
with SUI.
The second aim is to compare
changes in parameters obtained
in voids diaries and the
quality-of-life questionnaire.
31 women with SUI




In both groups 24 sessions for 8 weeks
(3 times a week). Before the training 3
instructional sessions (the same for both
study groups) BF: time of session:
30–50 min. PFM strength training began
with 80% of the MVC (3 s of contraction/6 s
of relaxation). The number of short
contractions increased accordingly in the
following weeks (from 21 units to 60 units).
Endurance training included 45 to 120
units (contraction/relaxation at 60% MVC
with 90 s interval between
series—contraction/relaxation for 5 s at
1–4 week and 10 s at 5–8 week). PG: time of
one session: 40–50 min. The training
consisted of Pilates exercises and voluntary
PFM contractions. Assessment: KHQ, a
voiding diary, sEMG, ICIQ-SF.
In both groups the number of episodes of
urinary incontinence decreased at each
measurement point. There were no
differences between the groups in the
frequency of urination and the number of
episodes of incontinence. After 8 weeks of
exercise and 6 months of observation, it
was shown that the Pilates method better
improves the quality of life of women with
SUI than BF training (KHQ). In turn,
ICIQ-SF showed similar effectiveness of
both Pilates and BF trainings.
SUI—Stress urinary incontinence; PFMT—pelvic floor muscles training; BF—biofeedback; KHQ—the King’s Health Questionnaire, ICIQ-SF—International Consultation on Incontinence
Questionnaire—Short Form, PFM—Pelvic muscles floor, I-QOl—the Incontinence Quality-of-Life Questionnaire, EMG—electromyography, ES—electrical stimulation, QOL—quality of life,
MOS—Modified Oxford Scale
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6.2. Manual Therapy
Pelvic Floor Dysfunction (PFD) e.g., urinary incontinence is difficult to treat because of the many
entangled factors: urologic, gynecologic, psychologic, and musculoskeletal factors [79]. The PF, as
with any skeletal muscle, may have increased or decreased muscle tone [80]. Hypo- and hypertonia of
PF causes various ailments that should be treated individually [81]. It should be also remembered
that organs and muscles are connected by fascia. Endopelvic fascia is continuous with visceral and
abdominal fascia, diaphragm, posterior intermuscular septum, and fascia of adductors. Any disorders
in hip, core muscles may affect PFD [80].
There are studies confirming effectiveness of dry needling [80], trigger points (TrP) releasing [82,83]
and massage [84] in reducing urinary incontinence symptoms and pelvic pain. TrP manual compression
and dry needling result in softening of the taut band, oxygenate the problem muscles area, relieve
pain, and improve disturbed movement patterns [83]. Massage is also recommended in PFD treatment.
Studies indicated that massage of the abdominal muscles and directly of urinary bladder improves
bladder function and blood distribution in this area. Then occurs cell regeneration, muscle elasticity
and contractility increase, and muscle tone normalizes [84].
6.3. Electrical Stimulation
Electrical stimulation is one of the most commonly used therapeutic methods in the treatment
of UI [85]. The method of electronic PFM stimulation was first described in 1963 by Caldwell. It is a
noninvasive, passive treatment that induces muscle contraction [86]. Electrical stimulation can be an
individual therapy or can be combined with PFMT or BF, which, according to research, significantly
increases its effectiveness not only in urine but also in fecal incontinence [87]. However, because of
pain or discomfort experienced by the patient during the procedure, it is not recommended as the
first line of UI treatment [88]. The arrangement of the electrodes depends on the type of target tissue.
For muscle tissue, the electrodes should be located on the muscle belly, while in the nerve tissue,
they should be located along the course of the nerve or one electrode at the motor’s nerve point and
the other on the target muscle [89]. Current flow causes contraction of the PFMs with simultaneous
inhibition of detrusor muscle activity [90]. Distinguished was transvaginal [91] as well as surface
electrical stimulation [61].
Electrical stimulation does not stimulate the muscle directly, but through motor nerves. Therefore,
frequencies above 70 Hz may cause neuromuscular damage [92]. The optimal stimulation frequency is
50 Hz for SUI [88] and 10–20 Hz for UUI [93]. The selection of appropriate parameters in electrotherapy
is required to obtain an increase in muscle strength [94]. Electrical stimulation significantly reduces
the symptoms of UI [61]. A significant reduction in UI symptoms was noted after both surface
electrostimulation and transvaginal electrical stimulation [95,96]. Pereira et al. [96] noted a significant
reduction of urinary loss events after 6 weeks of electrotherapy in women with SUI compared to that
in patients without treatment. In addition, electrical stimulation is characterized by a low risk of side
effects. In the study by Alves et al. [97], no side effects, such as pain, discomfort, or vaginal infection were
noted in patients in both groups. Franzén et al. [98] examined the long-term effect of electrostimulation
on the occurrence of UI. After 6 months from the end of therapy, nearly 73% of the examined patients
reported an improvement in continence [98]. The long-term effect of electrostimulation has also been
studied by Fürst et al. [99]. After 3 months, a significant increase in the time between voids was
observed in the examined patients [from 2.24 ± 1.09 to 3.35 ± 0.86 h (p < 0.0001)]; similar differences
were, however, not observed after 96 months [99]. A detailed description of the studies included in the
review is presented in Table 3.
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Table 3. Characteristic of selected studies on the effects of electrical stimulation on the pelvic floor muscles (PFMs) activity and/or severity of urinary incontinence
(UI) symptoms.
Reference Main Objective Patient Characteristics Study Description Outcome
Alves et al. (2011) [97]
Comparison of the effectiveness
of low or medium frequency
intravaginal neuromuscular
electrostimulation (NMES) in
the treatment of SUI in women.
20 women with SUI, aged
42–64(G1) NMES+MF: 10
(G2) NMES+LF: 10
Time: 20 min, 2 times a week, for 6
weeks, NMES at max tolerable intensity:
G1: biphasic frequency (2000 Hz),
100 ms, time on: off 4: 8 s modulation
frequency: 50 Hz, G2: biphasic, 50 Hz,
700 ms, time on: off 4: 8 s
Assessment: perineometry examination
for PFM, 1 hpad test, VAS for UI
discomfort, the voiding diary.
Both low and medium frequency
stimulation significantly reduced the
micturition frequency (voiding dairy),
the intensity of urine loss (pad test),
and the degree of discomfort associated
with UI (VAS) as well as PFM straight
improved (perineometer) as observed
by comparing the results of pre- and
post-treatment. There were no
significant differences between groups,
indicating comparable efficacy of
both stimulations.
Correira et al. (2014) [95]
Evaluation of the effectiveness
of surface versus intravaginal
electrical stimulation (SES vs.
IVES) in the treatment of SUI
in women.
45 women with SUI
Aged over 50SES = 15
IVES = 15
Control = 15
Time: 20 min, 2 times a week, for
12 weeks, ES at max tolerable intensity:
Frequency: 50 Hz,
Pulse time: 700 ms,
Work/rest cycle: 4/8 s, rise/fall: 2/2 s
SES: 4 surface electrodes: 2 in the




Assessment: 1 h pad test,
KHQ, PERFECT scheme, Modified
Oxford Scale, and perineometer for
PFM evaluation
Both SES and IVES significantly
reduced the intensity of urine loss (pad
test), and improved the patients’
quality of life (KHQ); however, only
IVES significantly improved the
strength of PFM (Oxford Scale).
No differences were noted in the
control group as well as between the
IVES and SES groups except for the
strength of PFM.
Both IVES and SES improved urinary
retention, but only IVES significantly
improved PFM strength.
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Table 3. Cont.




efficacy and safety of
self-administered external and
intravaginal electrical
stimulation (NMES) in women
with SUI.
148 women with SUI, aged
18–65 that did not benefit from
pretrial Kegel exercise SES = 74
IVES = 74
12 weeks, at home after professional
instruction, once daily for 5 days
per week
SES: 30 min, 50 Hz, 620 µs, 0.5 s ramp
up/down, on/off 5/5 s (INNOVO device)
IVES: 20 min, 50 Hz, 300 µs, 1 s ramp
up/down, on/off 5/10 s (iTouch device)
Assessment: pad test, 7-day voiding
dairy, I-QOL, PISQ-IR, PGI-I, adverse
events assesses
In both groups, there was a significant
reduction in both the frequency
(voiding dairy) and severity of urine
loss (pad test) in the number of used
pads and the I-QOL result in relation to
the initial value (with no clinically
relevant differences between
the groups).
Both devices were well-tolerated, but
external stimulation showed better
compliance. The main side effects
included discomfort, infection,
and pain.
Pereira et al. (2012) [96]
Assessment of the effectiveness
of superficial electrical
stimulation (SES) in older
women with SUI compared to
no treatment.
14 women with SUI
Aged over 60SES = 7
Control = 7
Time: 20 min, 2 times a week, for 6
weeks, ES at max tolerable intensity:
Frequency: 50 Hz,
Pulse time: 700 ms,
Work/rest cycle: 4/8 s, rise/fall: no data
SES: 4 surface electrodes: 2 in the
suprapubic region and 2 medial to
ischial tuberosity
Control: no treatment
Assessment: 1 h pad test,
KHQ, PFM pressure.
In the SES group, there was a significant
improvement in the loss of urine (pad
test) and improved quality of life
(KHQ) compared to the initial value
and the control group. There were no
differences between the SES and control
groups in terms of PFM pressure.
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Reference Main Objective Patient Characteristics Study Description Outcome
Mateus-Vasconcelos
et al. (2018) [59]
Assessment of the effect of
vaginal palpation, vaginal
palpation with posterior pelvic
tilt, and vaginal electrical
stimulation in facilitating
voluntary contraction of the
PFM in women.
132 women with week PFM (0–1
in Modified Oxford Scale), Aged
> 18:PG (vaginal palpation) = 33;
PTG (vaginal palpation with
posterior pelvic tilt) = 33;
ESG (intravaginal electrical
stimulation) = 33;
CG (control group) = 33
For PG, PGT, and ESG: 1 session per
week (3 interventions) with no PFMT
at home
PG: bidigital vaginal palpation to
proprioceptive stimulation: therapist
request 3 series of 10 contraction (6 s)
with 6 s rest, and 6 quick contraction on
the end
PTG: as above but with posterior pelvic
tilt movement during PFM contraction
ESG: 20 min, 50 Hz, 200 ms, 5:10 on: off
CG: verbal instruction for daily
PFM contraction
Assessment: The Modified Oxford
Scale, ICIQ-UI-SF
All groups reported significant
improved in PFM contraction capacity
(Oxford Scale), but PTG and PG groups
were significantly better than other
groups. UI symptoms in terms of
frequency, severity, and impact on
quality of life (ICIQ-UI-SF) was also
improved in all groups, but the PG
results were significantly better than
those of the other groups.
The results suggest that vaginal
palpation with or without posterior
pelvic tilt was more effective in PFM
facilitating than electric stimulation.
Franzén et al. (2010) [98]
Assessment of whether
electrical stimulation may be
more effective than
pharmacotherapy in a patient
with UUI.
61 women with UUI, Aged ≥
60ES = 31
T (Tolterodine) = 30
SES: Time: 20 min, 10 therapies, 1–2
times a week, for 5–7 weeks,
Frequency: 5–10 Hz at max
tolerable intensity:
T: tolterodine SR 4 mg; 1 time per day
(if intolerable, reduced to 2 mg) for
6 months
For both: evaluation at 6 weeks and
after 6 months
Assessment: KHQ, 48 h bladder diary,
use of pads,
In both the SES and T groups, there was
a significant decrease in the number of
voids and a significant improvement in
the quality of life of patients. There
were no differences between the
effectiveness in the ESE and T groups.
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Reference Main Objective Patient Characteristics Study Description Outcome
Fürst et al. (2014) [99]
Comparison of therapeutic
efficacy of intravaginal electric
stimulation (IVES) alone or
IVES electrical stimulation
combined with PFMT in women
with SUI.
35 women with SUI, Aged
49.6 ± 10.6IVES + PFMT = 17
IVES = 18
IVES parameters:
30 min, 2 times a week for 3 months
4 Hz (15 min, 1 ms), 50 Hz (15 min,
700 µs), 20 mA, work/rest cycle: 4/8 s
PFMT: 30 min, twice a week under the




PFM strength measured by
maintenance of intravaginal cones.
In both groups, after 3 months, there
was a significant increase in time
between voids and a reduction in
nocturia and urinary loss episodes.
There were no differences between
the groups.
The results suggest that the
combination of IVES with PFMT does
not increase the effectiveness of SUI
symptom treatment according to the
analyzed parameters.
Schreiner et al. (2010)
[101]
Evaluation of the efficacy of
transcutaneous electrical
stimulation of the tibial nerve
(TTNS) for the treatment of UUI
in older women.
51 women with UUI, aged
TTNS: 26
Control: 26
In both groups, all patients were
instructed to perform Kegel and
bladder training for 12 weeks.
In the TTNS group, patients were also
subjected to electrical stimulation of the
tibial nerve for 30 min, once a week for
12 weeks (10 Hz, 200 ms, 10–50 mA).
Assessment: physical examination,
3-day voiding dairy, KHQ, ICIQ-UI-SF.
In both groups, there was a significant
improvement in reducing the frequency
of voiding episodes compared to
pre-intervention values. However, the
final values obtained in the
electrostimulation group were
significantly lower than those in the
control group with Kegel and bladder
training alone.
SUI—stress urinary incontinence; NMES—neuromuscular electrostimulation; PFM—pelvic floor muscle; UI—urinary incontinence; SES—surface electrical stimulation; IVES—intravaginal
electrical stimulation; KHQ—King’s Health Questionnaire; I-QOL—Incontinence Quality-of-Life Scale; PISQ-IR—pelvic organ prolapse incontinence sexual questionnaire IUGA
revised PGI-I Patient Global Impression of Improvement; ICIQ-UI-SF—International Consultation on Incontinence Questionnaire—Short Form; UUI—urge urinary incontinence;
TTNS—transcutaneous electrical tibial nerve stimulation.
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6.4. Magnetic Stimulation
The use of magnetic stimulation (MS) or extracorporeal magnetic innervation (ExMI) in
non-surgical treatment of UI has raised extensive controversy, but recent studies have provided
evidence of the effectiveness of this therapy. In 1998, PFM magnetic stimulation was approved by
the US Food and Drug Administration (FDA) as a conservative treatment method of UI [102] and
was indicated among non-surgical UI therapies in the latest guidelines of European Association of
Urology [103]. Although the European Association of Urology (EAU) 2018 guidelines, based on
evidence from 2007 and 2008 (two papers), do not recommend the use of MS in adult women with
SUI (level of evidence: 2a), it however omits an important study conducted recently, which will
be presented below. MS is a noninvasive, passive method of stimulating the roots of the sacral
nerves or PFMs [104]. The MS method uses a special chair with a therapeutic head placed in the
seat; as the magnetic field can penetrate through clothes, stimulation can be carried out in clothing,
which significantly increases the comfort of therapy [105]. The head creates a magnetic field that
penetrates the pelvic organs, acting directly on the motor fibers of the nerves. MS stimulates the
PFMs to repeatedly contract and relax, which are clearly experienced during the procedure [106].
Moreover, MS-induced PFM contraction simultaneously inhibits the reflex mechanism of emptying the
bladder [107], and consequently leads to an increase in bladder capacity in both female bladder outlet
obstruction [108] as well as in UUI or SUI [109]. MS also increases the strength of PFMs [110], with
no adverse effects [103,111]; level of evidence: 1b. In addition, MS therapy significant decreases the
intensity of urinary incontinence symptoms in women with SUI [112,113] and UUI [109] measured in
1 h pad test or voiding diary. The beneficial effect of MS was also noted in the reduction of UI incidents
in patients after radical hysterectomy due to cervical cancer [114]. Moreover, it also causes short- and
long-term improvement in the quality of life of women with SUI [115] while improving the severity of
depression symptoms observed in these women [106,116]. It is also important to highlight the findings
of Koh et al. [108] who showed comparable efficacy of Extracorporeal Magnetic Innervation (ExMI)
as alpha-blocker monotherapy in the treatment of female bladder outlet obstruction. According to
Weber-Rajek et al. [106], ExMI leads to a significant decrease in myostatin levels in patients with SUI;
myostatin is an inhibitor of myogenesis [117,118], which may play an important role in the remodeling
and regeneration of PFM. For an optimal therapeutic effect, the recommended dose of magnetic field
is between 5 and 50 Hz [112,113,119] and it is dependent on the intended purpose of the therapy.
Lower frequencies (5–10 HZ), as in ES, are used to inhibit detrusor activity, while higher (20–50 Hz)
are effective in stimulating PFM contraction and closing the urethra [112,120]. MS is an alternative to
electrical stimulation (ES); however, compared to ES, it is a painless method and more comfortable for
the patient [105]. MS is assessed by patients with SUI as a well-tolerated and satisfactory method [121].
A detailed description is presented in Table 4.
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Table 4. Characteristic of selected studies on the effects of magnetic stimulation on the pelvic floor muscle (PFM) activity and/or severity of urinary incontinence
(UI) symptoms.




Evaluation of the effectiveness
of extracorporeal magnetic
innervation (ExMI) in the
treatment of women with SUI.
52 women with SUI, aged
61–76ExMI = 28
Control. = 24
ExMI: 15 min, 3 times a week, for 4 weeks, 2.0 T
at 50 Hz, for 8 s on/4 s off, increasing from 20% to
100% in subsequent sessions
Control: without intervention Assessment:
QUID, GSES, RUIS, BDI, Myostatin level
In ExMI, but not in control group, the UI severity,
depression, and myosin level were significantly
reduced relative to the initial value.
There were no differences in the final test values
between the ExMI and control groups.
Weber-Rajek et al.
(2020) [116]
Evaluation of the effectiveness
of PFMT and ExMI in the
treatment of women with SUI.





PFMT: supervised 12 sessions, 45 min, 3 times a
week for 4 weeks
ExMI: 12 sessions, 15 min, 3 times a week for
4 weeks (2.0 T, 50 Hz, for 8 s on/4 s off, increasing
from 20% to 100% during the
subsequent sessions
Control: without intervention
Assessment: RUIS, BDI-II, GSES, KHQ
Both the PFMT and ExMI intervention induced
significant improvement in the severity of UI
(RUIS) and a reduction in depression symptoms
(BDI-II), while improving the quality of life
(KHQ). In addition, ExMI treatment improved
self-efficacy beliefs (GSES) of patients with SUI.
Lim et al. (2017)
[122]
Evaluation of the effectiveness
of pulsed magnetic stimulation
in the treatment of SUI as a
non-surgical treatment method.




MS: 16 or 32 sessions, 20 min, twice a week,
50 Hz, for 8 s on/4 s off;
Sham: as above but with restricted transmission
of magnetic pulse
Assessment: ICIQ-UI-SF, 1 h pad test, PFM
examination by perineometer, PGI-I,
ICIQ-LUTSqol; follow-up at 1, 2, 5, 8, and
14 months
Long-term response was observed: The MS
group showed significantly lower ICIQ-UI-SF
values, lower frequency and severity of UI, and
higher PGI-I values than in the Sham group.
Objective and subjective cure values were higher
in the MS group than in Sham group.
Gilling et al. (2009)
[123]
Assessment of the effectiveness
of extracorporeal
electromagnetic stimulation in
the treatment of SUI symptoms
in patients undergoing
unattended PFMT.




For both: women were educated about PFM and
received low-intensity PFMT program to
home practice.
MS: 3 times a week for 6 weeks
10 min at 10 Hz, 3 min rest, 10 min at 50 Hz
Sham: same as above but with blocked
transmission of magnetic waves through an
aluminum plate
Assessment: 3-day bladder diary; 24-h pad test,
CVM, and perinometry for muscle score, I-QOL,
KHQ, video-urodynomics
Both MS and Sham patients, performing only
unattended PFMT, achieved improvement in the
intensity of UI symptoms (pad test) and quality
of life.
There were no statistically significant differences
between the MS and Sham groups, suggesting a
similar efficiency of the MS stimulation
parameters used in these studies for
unattended PFMT.
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Table 4. Cont.
Reference Main Objective Patients Characteristic Study Description Outcome
Yamanishi et al.
(2014) [113]
Evaluation of the effectiveness
and safety of MS in the




Time: 25 min, twice a week, for 6 weeks
Magnetic field parameters: Active: 560 mT,
300 µs, 10 Hz
Sham: 114 mT, 300 µs; 1 Hz, 5 s on/5 s off cycle,
Assessment: The bladder diary; IPSS QOL
MS effectively reduced UUI symptoms in
patients with OAB.
A significant reduction in the leak per week and
urgency per 24 h and increase in mean and
maximum voided volume per micturition was




The effect of magnetic
stimulation on the treatment of
SUI in women refractory to
PFMT.
For both: women with no effects
of PFM training for more than
12 weeks Active =18
Sham =12
For both: 20 min, once per week for 10 weeks
Magnetic field parameters: 5 s on/5 s off cycle,
300 µs
Active: 272 mT, 50 Hz,
Sham: 114 mT, 1 Hz
Assessment: urodynamic examination, the
voiding diary, the 24 h pad test, ICIQ-SF,
ICIQ-QOL, ALPP
MS effectively reduced UI symptoms in
PFMT-resistant women with SUI.
A significant reduction in the number (voiding
diary) and intensity (pad test) of UI episodes and
increase in ALPP was noted in the active MS
group, but not in the Sham group.
ExMI: extracorporeal magnetic innervation; SUI: stress urinary incontinence; QUID: The Questionnaire for Urinary Incontinence Diagnosis; GSES: The General Self-Efficacy Scale; RUIS:
The Revised Urinary Incontinence Scale; BDI: Beck Depression Inventory; PFMT: pelvic floor muscle training; KHQ: King’s Health Questionnaire; MS: magnetic stimulation; SLPP: The
stress leak-point pressure; CVM: Circumvaginal muscle rating score; I-QOL: Incontinence Quality-of-Life Scale; PGI-I: Patient Global Impression of Improvement; ICIQ-LUTSqol: ICI
Questionnaire-Lower Urinary Tract Symptoms Quality of Life; IPSS QOL: International Prostate Symptom Score-Quality of Life; ICIQ-SF: International Consultation on Incontinence
Questionnaire—Short Form; ICIQ-QOL: International Consultation on Incontinence Questionnaire—Quality of Life; ALPP: Abdominal leak-point pressure.
J. Clin. Med. 2020, 9, 1211 21 of 32
6.5. Whole-Body Vibration
Whole-body vibration training (WBV) is a valuable tool supporting both sports training and
physiotherapy [124]. The use of a vibrating platform in exercises supports the therapeutic process
in patients with nonspecific lumbar pain [125], multiple sclerosis [126], Parkinson’s disease [127], or
hemiplegia [128]. The method consists of carrying out a set of exercises performed on a vibrating
platform that oscillates at a given frequency and amplitude [129]. Mechanical vibration conducted
during exercise leads to a change in muscle length. Information about muscle lengthening is
transmitted by sensory nerves to the spinal cord and consequently provokes muscle contraction
through the activity of α-motor neurons [130]. The induction of myoelectric activity during WBV
is well documented [131,132]. Moreover, studies have confirmed that high-intensity synchronous
WBV (frequency 40 Hz, amplitude 4 mm) with a long duration (60 and 90 s) elicits a response from
PFM, leading to an increase in the mean amplitude of the sEMG signal from PFMs in young continent
women [133]. Moreover, studies have indicated that the activation of PFM is caused by both sinusoidal
(S-WBV) and stochastic resonance WBV (SR-WBV), and the level of PFM activation depends on
the intensity of the vibration [134]. It has also been shown that SR-WBV-induced PFM contraction
is higher than voluntary muscle contraction, which is particularly pronounced in the case of PFM
weakened by delivery [134]. However, there were no differences in efficiency between continuous
and intermittent RS-WBV [130]. WBV also exerts positive effects on dysfunctional PF in women with
UI. Farzinmehr et al. [135] showed that 4-week WBV training has a comparable therapeutic effect to
PFMT, causing a significant reduction in UI symptoms and improving the quality of life of patients,
which was also maintained in the 3-month follow-up. A detailed description of the studies included in
the review is provided in Table 5.
A slightly different form of vibration therapy is the use of techniques directly affecting PFM using
a transcutaneous vibratory perineal stimulation [136] or intravaginal vibratory stimulation [137–139].
These techniques use different stimulation parameters from those used in the indirect techniques
described above for review see [129,140]. Nevertheless, studies show that the intravaginal vibratory
stimulation significantly increase the effectiveness of PFMT [137], while being more effective in
improving PFM strength than transvaginal electrostimulation when applied in women with SUI.
Hence, it can be considered to be a support for the therapeutic process in patients with PFM or UI
dysfunction. An overview of the mentioned articles is presented in Table 6 below.
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Table 5. Characteristic of selected studies on the effects of whole-body vibration (WBV) training on the pelvic floor muscle (PFM) activity and/or severity of urinary
incontinence (UI) symptoms.
Reference Main Objective Patient Characteristic Study Description Outcome
Lauper et al. 2009 [134]
Verification of the effectiveness
of sinusoidal and stochastic
resonance WBV on PFM
activation in healthy and
postpartum women.
Control group: 23 healthy women;
aged 18–40
Post-partum group: 26 women,
aged 18–40; 8 weeks to 1 year after
delivery with a week PFM (0–3 in
Modified Oxford Scale)
Verification of PFM activity in sEMG
during different type and intensity of
vibration measured with and without
MVC of PFM.
S-WBV: 5, 10, 15, 20, or 25 Hz with 2 or
4 mm amplitude.
SR-WBV: 2, 4, 6, 8, 10, or 12 Hz.
Assessment: PFM activity in sEMG
Both vibration methods effectively
activated the PFM, minimal parameter
is 6 Hz for SR-WBV and 15 Hz/4 mm
for S-WBV.
SR-WBV induced significantly higher
level of PFM activation than sinusoidal
WBV, and exceeds the value of MVC in
postpartum group (127%; 12 Hz).
Luginbuehl et al. 2012 [130]
Comparison of continuous and
intermittent stochastic
resonance WBV (SR-WBV) to
determine the optimal vibration
methodology for
PFM activation.
Group 1: 28 women (8 weeks to
1 year after delivery) aged 18–45;
Group 2: 22 women (more than
year after childbirth or nulliparous)
aged 18–80;
All with SUI
SR-WBV = 8 Hz
Continuous: 3 sets of 60 s WBV with 60 s
rest between sets;
Intermittent: 3 sets of 12 × 5 s WBV with
10 s rest between WBV and 60 s rest
between sets.
Assessment: PFM strength in sEMG and
Modified Oxford Scale
The training provoked PFM activation
at only 50–70% of MVC.
There were no differences in PFM
activation between the tested
modalities (continuous versus
intermittent). For practical reasons, the
authors suggest the use of continuous
vibration in clinical practice.
Farzinmehr et al. 2015 [135]
Assessment of the effectiveness
of WBV training in improving
the strength of the PFMs in
women with SUI.
RCT: 43 women with SUIWBVT
group—21;
PFMT group—22;
Training for both: 3 times a week for 4
weeks (a diversified,
progressive program).
WBVT: 30–50 Hz; 2.5–5 mm;
rest 30–60 s
PFMT: supervised training consisting of
3–4 sets of 15–20 repetitions with 60 s
break between sets.
Assessment: PFM strength in sEMG and
Modified Oxford Scale, incontinence
severity in VAS; Quality of Life—I-QOL
In both groups, a significant (p = 0.0001)
post-training improvement was
obtained in terms of reducing UI
severity, increasing PFM strength, and
improving the quality of life.
In addition, there were no differences in
the above parameters between the
WBVT and PMFT groups, which proves
the equal effectiveness of both methods.
Stania et al. 2015 [133]
Assessment of bioelectric PFM
activation during low and
high-intensity synchronous
WBV in healthy women.
RCT: 33 continent nulliparous
LI-WBV group: 12, aged 22.4 ± 1.6;
HI-WBV group: 10, aged 21.4 ± 1.7;
CTR w/o WBV: 11, aged 22.7 ± 1
Three sets of static WBV exercises (30, 60,
or 90 s), performed in a random order,
with a 60 s rest between them:
LI-WBV group: 20 Hz, 2 mm
HI-WBV group: 40 Hz, 4 mm.
Assessment: PFM sEMG
Long-term (60, 90 s), high-intensity (40
Hz) WBV training significantly caused
a significant increase in PFM activation,
which was not observed in
low-intensity training.
SR-WBV—stochastic resonance whole-body vibration; PFM—pelvic floor muscle; RCT—Randomized Clinical Trial; LI-WBV—low-intensity whole-body vibration; HI-WBV—high-intensity
whole-body vibration; WBVT—whole-body vibration training; PFMT—pelvic floor muscle training; I-QOL—The Incontinence Quality-of-Life Questionnaire; VAS—Visual Analog Scale.
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Table 6. Characteristic of selected studies on the effects of direct vibration on the pelvic floor muscle (PFM) activity and/or severity of urinary incontinence
(UI) symptoms.
Reference Main Objective Patient Characteristic Study Description Outcome
Ong et al. 2015 [137]
Effectiveness of PFM exercises
combined with the Vibrance
Kegel Device (VKD) compared




PFMT + VKD: 21For both:
women with SUI, age over
18 years
For both: 16 weeks, control and PFM
re-education at 0–4–16 week.
PFMT group: daily PFM exercise according
to the protocol and 1 per month with a
therapist (20 min);
PFMT + VKD group: daily PFM training
with VKD as BF.
Assessment: Australian Pelvic Floor
Questionnaire (APVQ), Modified Oxford
Scale for PFM activity
In the PFMT + VKD group, SUI score
(APVQ) was improved after just 4
weeks. The values equalized with those
of the PFMT group at week 16.
In addition, after 4 weeks, the strength
of PFM in the PFMT + VKD group was
significantly higher than that in the
PFMT group, which was also
maintained at week 16.
VKD can be a valuable and effective
tool to support PFMT.
de la Torre et al. 2017 [138]
Assessment of the effectiveness
of multimodal vaginal toning
therapy in improving of bladder
symptoms and quality of life in
women with postpartum SUI
48 women with postpartum SUI,
aged 30–59
Stimulation: daily for 45 days, at home for
up to 10 min of intravaginal multimodal
stimulation (light therapy: 662–855 nm;
heat: 41 ◦C; vibration: 80–110 Hz).
Assessment before and post-treatment:
UDI-6, IIQ-7, FSFI, FSDS-R, Oxford Scale
for PFM strength, 1 h pad test
An improvement of over 50% was
noted after therapy in the following
areas: loss of urine in 1-h pad test in
84% respondents; improving the quality
of life (UDI-6) in 92% of respondents
and in 85% respondents (IIQ-7). The
strength of PFM also increased
significantly. The level of patient
satisfaction with therapy reached 83%.
Rodrigues et al. 2019 [139]




(IVES) in women with PFM
dysfunction (without voluntary
PFM contraction)
Group IVVS = 21
Group IVES = 21 Women’s age>
18 years and Grade on the
Modified Oxford Scale = 0 or 1
For both: once weekly (20 min) for 6 weeks
IVVS parameters: 95 Hz; amplitude:
1.5 mm; work/rest time: 8/16 s
IVES parameters: 50 Hz; pulse width:
300 ms; work/rest time: 8/16 s; the current
was adjusted to the patient’s individual
tolerance. Assessment of PFM: Modified
Oxford Scale, New PERFECT
scale; ICIQ-SF
After 6 weeks, both groups showed
improvement in UI as measured by
ICIQ-SF, without intergroup differences.
There were no post-therapeutic
differences between IVVS and IVES in
terms of PFM functions such as
endurance, fast contraction, and
repetition. However, after vibration
training, the PFM strength significantly
increased relative to that in the
IVES group.
PFM—pelvic floor muscle; VKD—Vibrance Kegel Device; SUI—stress urinary incontinence; PFMT—pelvic floor muscle training; APVQ—Australian Pelvic Floor Questionnaire;
UDI-6—Urogenital Distress Inventory Short Form; IIQ-7—Incontinence Impact Questionnaire—Short Form; FSFI—Female Sexual Function Index; FSDS-R—Female Sexual Distress
Scale—revised 2005; IVVS—intravaginal vibration stimulation; IVES—intravaginal electric stimulation.
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7. Conclusions
As indicated above, physiotherapy is certainly an important element of conservative treatment of
UI; however, its effectiveness is limited to less advanced conditions. In advanced UI stages, however,
physiotherapy is an important element in preparing the patient for surgical treatment, significantly
increasing the success of surgery. Moreover, physiotherapy significantly improves the quality of life of
women with UI [136]; however, to achieve optimal therapeutic effects, it is sometimes beneficial to
use a combination of several physiotherapeutic techniques. PFMT and ES are the most commonly
used therapies for treating UI. In the first line EAU recommends PFMT to prevent and treat UI
(level of evidence: 1). However, for many women, isolated voluntary PFM contraction is a major
concern. Studies show that often patients with UI are unable to perform isolated voluntary and
involuntary PFM contraction; hence, in this case, basing the therapy only on exercises will be ineffective.
In these situations, it becomes extremely important to use techniques focused on PFM sensitization.
Sometimes it will be necessary to use palpation or apparatus techniques, but without PFM activation,
the implementation of training programs will be ineffective. Electrical stimulation [59,95–101] and
biofeedback [57,75,78] can be used in addition to PFMT or to help women to initiate a contraction
and improve therapeutic effects (level of evidence: 2). In such cases, it is a preferable activation of
PFM to fully use the potential of the female pelvic floor. Recent studies [112,116,122] suggest that MS
induces improvement in the severity of incontinence (level of evidence: 2); however, EAU does not
recommend using magnetic stimulation to treat UI (strong evidence) and they do not mention vibration
training [103]. EAU guidelines do not include the latest RCT work indicating the effectiveness of the
above techniques in reduction of UI symptoms, these works are presented in this review. Our results
are familiar with other reviews regarding physiotherapeutic methods in UI (Table 7). Given the above,
it can be concluded that physiotherapy is an important and effective element of therapy in patients
with UI, with high levels of evidence. Nevertheless, the still small number of RCTs makes further
research necessary to increase their reliability and improve the effectiveness of therapy.
Table 7. Quality evidence of physiotherapy techniques in UI decisions in selected reviews.
Technique Level of Evidence GRADE Authors
PFMT I A Dumoulin et al. 2018 [141]
Electrical Stimulation IIa A Stewart et al. 2017 [142]
Biofeedback IIb A Bø 2012 [143]
Magnetic Stimulation IIb B He et al. 2019 [104]
Body Vibration IIb B Guedes-Aguiar et al. 2019 [129]
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Krakowska, N.; Kankowski, M.; et al. Management of stress incontinence in older women. J. Educ.
Health Sport 2019, 9, 209–220.
14. Senra, C.; Graca Pereira, M.G. Quality of life in women with urinary incontinence. Rev. Assoc. Med. Bras.
2015, 61, 178–183. [CrossRef]
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